Combined treatment of chronic prostatitis

V.P. Stus, V.V. Koshtura, E.V. Ganichev, I.M. Rusinko, Yu.Yu. Tsepelev, M.Y. Polion


Prostatitis is the third most prominent disease of the prostate after cancer and benign hyperplasia and accounts for more than 20% among andrological pathology. Chronic prostatitis / chronic pelvic pain syndrome (CP/CPPS) is one of the most common diseases in men. The frequency of CP/CPPS in the population ranges from 13.2% to 35%, and the peak in men up to 50 years old is 62.5%.

In study were included 60 patients with CP who were divided into 2 equivalent groups of 30 men. The first group received a combined treatment, the second – only antibiotic therapy. The effectiveness of treatment were estimated in the dynamics of clinical symptoms, the dynamics of subjective status assessment (NIH-CPSI questionnaire), laboratory parameters and ultrasound data.

The mean age of patients was 46.3±1.7 years in the combined treatment group and 45.7±1.2 years in the second group. According to the NIH-CPSI questionnaire, the number of points in the first group (5.7±0.5) after treatment was significantly lower (p <0.05) than in the second group (9.2±0.8).

The volume of the prostate in patients of the first group decreased from 24.7±2.1 to 22.5±1.1 cm3, while in the second group, respectively, from 29.7±2.03 to 23.9±1.5 cm3 . The number of residual urine in patients taking combination therapy decreased from 15.9±4.1 ml to 8.2±2.5 ml, and in patients in the second group – from 7.8±1.6 ml to 2.2±0,4 ml.

Conclusions. The treatment of chronic prostatitis should be complex, which means the simultaneous use of several drugs and methods acting on various parts of the pathogenesis of CP.


chronic prostatitis; combined therapy; levofloxacin


Аляев Ю.Г., Глыбочко П.В., Пушкарь Д.Ю. Урология. Российские клинические рекомендации. – М.: ГЭОТАР-Медиа, 2015. – 480 с.

Smith C.P. Male chronic pelvic pain: An update // Indian J Urol. – 2016. – V. 32 (1). – P. 34–39.

Polakwich A.S., Shoskes D.A. Chronic prostatitis/chronic pelvic pain syndrome: a review of eva luation and therapy // Prostate Cancer Prostatic Dis. – 2016. – V. 19(2). – P. 132–138.

Rees J. Abrahams M., Doble A. et al. Diagnosis and treatment of chronic bacterial prostatitis and chronic prostatitis/chronic pelvic pain syndrome: a consensus guideline // BJU Int. – 2015. – V. 116(4). – P. 509–525.

Божедомов В.А., Семенов А.В., Пацановская Г.М. и др. Репродуктивная функция мужчин при хроническом простатите: клинико-анамнестические и микробиологические аспекты // Урология. – 2015. – № 1. – С. 70–78.

Дорофеев С.Д., Красняк С.С. Применение левофлоксацина в урологической практике // Гострі та невідкладні стани у практиці лікаря. – 2013. – №1 (34).

Jon Rees, Mark Abrahams, Andrew Doble, Alison Cooper and the Prostatitis Expert Reference Group (PERG). Diagnosis and treatment of chronic bacterial prostatitis and chronic prostatitis/chronic pelvic pain syndrome: a consensus guideline // BJU Int. – 2015. – V. 116(4). – P. 509–525.

Canadian Guidelines on Sexually Transmitted Infections: [Электронный ресурс]. URL:

Anothaisintawee T., Attia J., Nickel J.C. et al. Management of chronic prostatitis/chronic pelvic pain syndrome: a systematic review and network meta-analysis // JAMA. – 2011. V. 305, N 1. – P. 78–86.

Nickel J.C., Downey J., Johnston B. et al. Predictors of patient response to antibiotic therapy for the chronic prostatitis/chronic pelvic pain syndrome: a prospective multicenter clinical trial // J. Urol. – 2001. – V. 165, N 5. – P. 1539–1544.

Lee J.C., Muller C.H., Rothman I. et al. Prostate biopsy culture findings of men with chronic pelvic pain syndrome do not differ from those of healthy controls // J. Urol. – 2003. – V. 169, N 2. – P. 584–587.